Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis

被引:2
|
作者
Cho, Wonyoung [1 ]
Park, Sangil [2 ,3 ]
Kim, Hyeon Jin [1 ,4 ]
Lee, Myeongcheol [1 ,4 ]
Choi, Yong Sung [5 ]
Yeo, Seung Geun [6 ,22 ]
Lee, Jinseok [7 ]
Koyanagi, Ai [8 ]
Jacob, Louis [9 ]
Smith, Lee [10 ]
Rahmati, Masoud [11 ,12 ]
Ahmad, Suhana [13 ]
Fond, Guillaume [14 ,15 ]
Boyer, Laurent [14 ,15 ]
Rhee, Sang Youl [1 ,16 ]
Lee, Seung Won [17 ]
Shin, Jae Il [18 ,21 ]
Woo, Ho Geol [2 ,20 ]
Yon, Dong Keon [1 ,4 ,5 ,19 ]
机构
[1] Kyung Hee Univ, Med Sci Res Inst, Ctr Digital Hlth, Coll Med, Seoul, South Korea
[2] Kyung Hee Univ, Dept Neurol, Med Ctr, Coll Med, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea
[4] Kyung Hee Univ, Dept Regulatory Sci, Seoul, South Korea
[5] Kyung Hee Univ, Med Ctr, Coll Med, Dept Pediat, Seoul, South Korea
[6] Kyung Hee Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Sch Med, Seoul, South Korea
[7] Kyung Hee Univ, Dept Biomed Engn, Yongin, South Korea
[8] Univ Barcelona, Parc Sanitari St Joan Deu, Res & Dev Unit, Barcelona, Spain
[9] Univ Paris Cite, Epidemiol Ageing & Neurodegenerat Dis, Paris, France
[10] Anglia Ruskin Univ, Ctr Hlth Performance & Wellbeing, Cambridge, England
[11] Lorestan Univ, Fac Literature & Human Sci, Dept Phys Educ & Sport Sci, Khorramabad, Iran
[12] Vali E Asr Univ Rafsanjan, Fac Literature & Humanities, Dept Phys Educ & Sport Sci, Rafsanjan, Iran
[13] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kelantan, Malaysia
[14] Aix Marseille Univ, AP HM, Hlth Serv Res & Qual Life Ctr, Dept Gynecol & Obstet, Marseille, France
[15] FondaMental Fdn, Creteil, France
[16] Kyung Hee Univ, Coll Med, Dept Endocrinol & Metab, Seoul, South Korea
[17] Sungkyunkwan Univ, Sch Med, Dept Precis Med, Suwon, South Korea
[18] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea
[19] Kyung Hee Univ, Dept Pediat, Coll Med, 23 Kyungheedae Ro, Seoul 02447, South Korea
[20] Kyung Hee Univ, Dept Neurol, Coll Med, 23 Kyungheedae Ro, Seoul 02447, South Korea
[21] Yonsei Univ, Dept Pediat, Coll Med, 50 Yonsei Ro, Seoul 03722, South Korea
[22] Kyung Hee Univ, Dept Otolaryngol Head & Neck Surg, Coll Med, 23 Kyungheedae Ro, Seoul 02447, South Korea
基金
新加坡国家研究基金会;
关键词
2003-2021; 2022; clinical feature; comparison; mpox; outbreak; prevalence; symptom; HUMAN MONKEYPOX; CONGO;
D O I
10.1002/rmv.2508
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
On 23 July 2022, the World Health Organization declared the global mpox outbreak as a public health emergency of international significance. The mpox virus (MPXV) that caused the outbreak was classified as clade IIb, which belongs to the West African clade. However, the relationship between MPXV clades and symptoms, as well as the severity of mpox outcomes, is not fully understood. Thus, we aimed to investigate the global mpox prevalence and the differences in clinical manifestations and outcomes among patients with mpox between pre-outbreak (2003-2021) and the current mpox outbreak. In this systematic review and meta-analysis, PubMed/MEDLINE, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were searched using the keyword "monkeypox" and "mpox" up to 13 October 2022. A random effects model was used to obtain the pooled prevalence and 95% confidence intervals. This study included 27 articles, and 5698 patients with mpox with 19 distinctive features from 19 countries across five continents were assessed. Patients with mpox during the 2022 mpox outbreak showed mild clinical manifestations and outcomes compared with those before the 2022 mpox outbreak: mild rash (relative ratio [RR]: 5.09, 95% confidence interval [CI]: 1.52-17.08), fever (0.68, 0.49-0.94), pruritus (0.25, 0.19-0.32), myalgia (0.50, 0.31-0.81), headache (0.56, 0.35-0.88), skin ulcer (0.32, 0.17-0.59), abdominal symptom (0.29, 0.20-0.42), pharyngitis (0.32, 0.18-0.58), nausea or vomiting (0.15, 0.02-0.93), conjunctivitis (0.11, 0.03-0.38), concomitant infection with HIV (1.70, 0.95-3 0.04), and death (0.02, 0.001-0.31). MPXV clade IIb exhibited higher infectivity but may cause mild disease symptoms and low mortality rate. It is important to consider MPXV infection in patients with mpox-related features and/or a history of sexual transmission to prevent the spread of the disease and recognise the current pandemic threat.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Comparison of clinical manifestations in mpox patients living with HIV versus without HIV: A systematic review and meta-analysis
    Shin, Hyoin
    Shin, Heeje
    Rahmati, Masoud
    Koyanagi, Ai
    Jacob, Louis
    Smith, Lee
    Rhee, Sang Youl
    Kwon, Rosie
    Kim, Min Seo
    Kim, Sunyoung
    Shin, Jae Il
    Min, Chanyang
    Cho, Wonyoung
    Yon, Dong Keon
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (04)
  • [22] A retrospective chart review and thematic analysis of patients seeking mpox vaccination during the initial outbreak in 2022–2023: evaluation of access, motivations, and stigma
    Kody Muncaster
    Chelsea Masterman
    Tamara Barnett
    Robert A. Kozak
    Erin Mandel
    Karen Campbell
    Mia J. Biondi MJ
    BMC Public Health, 24 (1)
  • [23] Comparative evaluation of the clinical presentation and epidemiology of the 2022 and previous Mpox outbreaks: a rapid review and meta-analysis
    Okoli, George N.
    Van Caeseele, Paul
    Askin, Nicole
    Abou-Setta, Ahmed M.
    INFECTIOUS DISEASES, 2023, 55 (07) : 490 - 508
  • [24] Mpox vaccine acceptance among healthcare workers: a systematic review and meta-analysis
    Mektebi, Ammar
    Elsaid, Mohamed
    Yadav, Tularam
    Abdallh, Fatima
    Assker, Mohamad
    Siddiq, Abdelmonem
    Sayad, Reem
    Saifi, Motaz
    Farahat, Ramadan Abdelmoez
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [25] Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks
    Li, Pengfei
    Li, Jiajing
    Ayada, Ibrahim
    Avan, Amine
    Zheng, Qinyue
    Peppelenbosch, Maikel P.
    de Vries, Annemarie C.
    Pan, Qiuwei
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (04): : 391 - 401
  • [26] Exploring Viral Genome Profile in Mpox Patients during the 2022 Outbreak, in a North-Eastern Centre of Italy
    Deiana, Michela
    Lavezzari, Denise
    Mori, Antonio
    Accordini, Silvia
    Pomari, Elena
    Piubelli, Chiara
    Malago, Simone
    Cordioli, Maddalena
    Ronzoni, Niccolo
    Angheben, Andrea
    Tacconelli, Evelina
    Capobianchi, Maria Rosaria
    Gobbi, Federico Giovanni
    Castilletti, Concetta
    VIRUSES-BASEL, 2024, 16 (05):
  • [27] Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis
    Pischel, Lauren
    Martini, Brett A.
    Yu, Natalle
    Cacesse, David
    Tracy, Mahder
    Kharbanda, Kolambi
    Ahmed, Noureen
    Patel, Kavin M.
    Grimshaw, Alyssa A.
    Malik, Amyn A.
    Goshua, George
    Omer, Saad B.
    VACCINE, 2024, 42 (25)
  • [28] The impact of immunosuppression on the mortality and hospitalization of Monkeypox: a systematic review and meta-analysis of the 2022 outbreak
    Azzam, Ahmed
    Khaled, Heba
    Salem, Haitham
    Ahmed, Ameer
    Heniedy, Amira M.
    Hassan, Hassan Samy
    Hassan, Ahmed
    El-Mahdy, Taghrid S.
    VIROLOGY JOURNAL, 2024, 21 (01)
  • [29] Association of HIV infection and hospitalization among mpox cases: a systematic review and meta-analysis
    Muhammed Shabil
    Shilpa Gaidhane
    R. Roopashree
    Mandeep Kaur
    Manish Srivastava
    Amit Barwal
    G. V. Siva Prasad
    Pranchal Rajput
    Rukshar Syed
    Anoop Dev
    Danish Kundra
    Ambanna Yappalparvi
    Prakasini Satapathy
    Quazi Syed Zahiruddin
    Harish Kumar
    Renu Sah
    Ganesh Bushi
    BMC Infectious Diseases, 25 (1)
  • [30] Global prevalence and correlates of mpox vaccine acceptance and uptake: a systematic review and meta-analysis
    Sulaiman, Sahabi Kabir
    Isma'il Tsiga-Ahmed, Fatimah
    Musa, Muhammad Sale
    Makama, Bello Tijjani
    Sulaiman, Abdulwahab Kabir
    Abdulaziz, Tijjani Bako
    COMMUNICATIONS MEDICINE, 2024, 4 (01):